Treatment.com AI Announces Appointment of Richard Atkins as Chief Operating Officer and Executive Team member
VANCOUVER, British Columbia, May 8th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to announce the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team. Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive management and M&A, highlighted by multiple multi-million dollar deals working with both major health-tech and software corporations. Mr. Atkins spent his formative career in software and technology including: networking, managed services, data centers & virtualization, omnichannel contact centers, CRM, enterprise search/ data analytics, cloud-based applications. However, for the past 15 years, he has brought his experience to healthcare, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions including:- (i) Digital Health – healthbots, symptom checkers, telehealth, Alexa voice and social media solutions (ii) National/Provincial teletriage services (iii) Managed PACS/RIS and LIM services in both public/private sectors (iv) EMR/Billing and HL7/FHIR interoperability. His experience includes multi-million dollar contracts with the NHS (England and Scotland); national/regional triage services in Australia, Europe and North America; building out formative triage services in Africa through to working with US based Health Navigator (acquired by Amazon Care in 2019), an acknowledged global innovator in clinical content for digital health solutions. More recently, Richard spearheaded sales for CloudMD from its start-up phase in 2019 through to sales revenues in excess of $100M in 2021. Dr. Essam Hamza, CEO of Treatment, comments: “We are very excited with the addition of Richard to the Executive Team. His extensive knowledge and international connections in this space will greatly accelerate our expansion plans. Richard understands the unique inflection point of our company and has committed to help with the execution of our aggressive commercialization phase.” Richard Atkins comments :“I am delighted at the opportunity to join an impressive team at Treatment.com AI and help optimize the opportunity for the outstanding and differentiated Global Library of Medicine (GLM). Platforms like the GLM are predicated on healthcare professionals trusting the accuracy and reliability of the clinical information support provided; using curated AI and proprietary algorithms, the GLM ensures this confidence. Of equal importance, at a time of challenges to healthcare systems globally, is the opportunity to truly impact change and support both our future generation (through the Medical Education Suite) and present day healthcare professionals. Finally, the company’s ethos and the platform itself offer a tangible path to delivering health equality in North America and globally.” The Company has granted 250,000 stock options to Mr. Atkins, exercisable at $0.60 and valid for a five-year term. The stock options are issued pursuant to the Company’s Stock Option Plan and are subject to vesting conditions. Further, the Company is pleased to announce that it has entered into an extension agreement with Sunburst Data Corp. (“Sunburst”) to extend the term of the marketing agreement previously announced February 29, 2024. The term has been extended an additional 6 months to end February 28, 2025 and the Company will compensate Sunburst an additional $400,000USD in connection with the marketing services over the extended term. The Company has also engaged 45 Degrees, Inc. of Cheyenne, WY, to provide advertising services including Google Ads, a social media program and video interviews, for a term of 6 months commencing on May 6, 2024, in consideration of a total of $50,000USD. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Medical School Renews Contract with Tech Co.
This move further validates the firm’s Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy. A leading U.S. medical school renewed its contract to use Treatment.com AI Inc.’s (TRUE:CSE; TREIF:OTCMKTS;939:FRA) Medical Education Suite (MES), the company announced in a news release. MES provides case-based clinical decision-making, testing, grading, and remedial action support to empower the healthcare professionals of tomorrow. “It underpins our focus on the next generation of clinicians, as well as streamlining the operational costs and time currently experienced by medical schools when running the premier exams (Objective Structure Clinical Exams, or OSCEs) designed to test student practical clinical decision-making and reasoning,” Chief Executive Officer Dr. Essam Hamza said in the release. Globally, 57 countries use OSCEs. MES also aims to minimize the administrative work in grading and create a consistent, real-time approach for case testing and scoring. “To underscore the accuracy of its platform, the company recently announced that a non-medical undergraduate using its artificial intelligence (AI) software passed a medical clinical exam, exceeding a 92% success rate,” wrote Technical Analyst Clive Maund in an April 22 report. Treatment.com AI is in discussions about MES with a number of other medical and nursing schools in the U.S. and internationally, the company noted. The potential to expand this line of business is sizable, given the States is home to 300 medical schools, 900 nursing schools, 227,000 students, and 145,000 residents/medical students. Products Positively Disrupt Healthcare With a mission to “dramatically disrupt how healthcare is delivered worldwide,” Treatment.com AI develops and provides medical software solutions for students, educators, and clinicians. The Vancouver, British Columbia-based firm continues to expand its pipeline of offerings. The company “should have a very bright future,” wrote Technical Analyst Clive Maund in a February 16 report. Treatment.com AI’s array of products is powered by its proprietary, AI-backed Global Library of Medicine (GLM), created with hundreds of credentialed clinicians worldwide, to ensure the highest qualified clinical information and support are delivered. According to the company, the GLM is “the most comprehensive and integrated online medical library.” Technical Analyst Clive Maund recommended Treatment.com AI as a Strong Buy for all time frames and indicated he planned to stay long in it. Beyond medical education and working with partners, the company sees its GLM being utilized by an array of enterprises, including Electronic Medical Records, Healthbots/Symptom Checkers, Virtual Health providers, Medical Call Centers, National Triage Services, or Health Information Lines/websites. Organizations may integrate with the GLM through an application programming interface (API), thereby allowing them to improve both clinical accuracy and efficiency of their clinical information support and enhancing processes, from back-office tasks to patient intake and care. For healthcare professionals, these include writing medical notes, providing guidance on differential diagnoses with probabilities, suggesting recommended and most important treatments and testing, and determining accurate billing codes. Sizzling Sector The healthcare market is rapidly growing around the world, and the use of AI in the space is increasing. As such, AI and healthcare combined are hot sectors, as data from Statista and Market and Markets show. The global AI healthcare market nearly doubled in value between 2021 and today, going from US$11 billion (US$11B) to US$20.9B. Between now and 2029, the market is expected to increase more than sevenfold, reaching US$148.4B. This value jump over the next four years represents a compound annual growth rate (CAGR) of 48.1%. CAGRs above 20% in the tech space are considered “excellent,” according to Wealthy Education. “The growth potential of this industry is enormous,” Maund wrote. “With Treatment.com AI having already developed its own platform, it is centrally placed to be a part of this.” According to Market and Markets, numerous factors are driving this market expansion. They include “the generation of large and complex healthcare data sets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, the rising number of partnerships and collaborations among different domains in the healthcare sector, and the growing need for improvised healthcare services due to imbalance between healthcare workforce and patients.” Catalysts: Additional Product Launches In H2/24, Treatment.com AI intends to make available two new, monthly, subscription-based, software-as-a-service (SaaS) solutions for students, residents, and other healthcare professionals: AI Patient and AI Doctor in a Pocket. Unveiled last month, these SaaS products are designed to enhance the training and clinical decision-making capabilities of the users. For the company, these new offerings could increase its revenue and expand its market penetration. Analyst: Rated Strong Buy In an April 22 report, Maund asserted that a new technical analysis of Treatment.com AI’s stock reveals it to be in a “new bull market” that appears “set not just to continue but to accelerate with the real possibility of spectacular gains ahead.” The trading pattern suggests the stock now is completing a small bull flag/pennant shape, an indicator of an impending upleg. Thus, Maund recommended Treatment.com AI as a Strong Buy for all time frames and indicated he planned to stay long in it. Ownership and Share Structure According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of Treatment.com AI. They are Chief Medical Officer, Chairman, and Director Dr. Kevin Peterson with 10.35% or 3.84M shares. Retail investors own the remaining 86.88%. There are no institutional investors currently. The company has 39,243,518 million outstanding shares and 25,940,377 free-float traded shares. Its market cap is CA$24,330,981, and its 52-week trading range is CA$0.10 to CA$1.20 per share. Important Disclosures: Treatment.com AI Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to
Treatment.com AI Announces Contract Renewal with Leading US Medical School
VANCOUVER, British Columbia, May 1st, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is excited to announce one of the leading US medical schools has agreed to a contract renewal utilizing Treatment’s Medical Education Suite (“MES”). Treatment is also in discussions with a number of other medical and nursing schools, both in the US and internationally. As reported previously, the market in the US alone comprises 300 medical schools; 900 nursing schools; 227,000 students and 145,000 residents/medical students. For schools, MES aims to (i) reduce associated time, resources and lower costs involved in creating national exams (i.e. MCQs; OSCE); (ii) minimize the administrative work in grading and (iii) create a consistent and real-time approach for case testing and scoring. The OSCE exams are practiced by 57 countries globally. Treatment also previously announced its intention to additionally launch in the second half of 2024, two new monthly subscription-based SaaS solutions for students, residents and other healthcare professionals. The Medical Education Suite is underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “I am delighted to announce this contract renewal and the strong and growing pipeline that we are building within the business. It underpins our focus on the next generation of clinicians, as well as streamlining the operational costs and time currently experienced by medical schools when running the premier exams (OSCE) to test student practical clinical decision making and reasoning. We also look forward to expanding our offerings to both the schools and in turn, their students and residents” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Federal funding could further boost Treatment.com AI’s healthcare initiatives
Treatment is bringing AI to the the next generation of healthcare professionals, supporting medical and nursing schools, who use its Global Library of Medicine to enhance future clinical skills of their students. As a Canadian company using AI to positively disrupt the healthcare sector, Treatment welcomed the recent news of a federal government plan to include a $2.4-billion fund in the upcoming budget intended to help sectors like health and agriculture develop artificial intelligence (AI) adoption strategies. The global AI healthcare market, valued at $11-billion in 2021, is projected to be worth $187-billion by 2030. “This will have a positive impact on costs and cost allocation for our healthcare organizations and governing bodies,” says Dr. Essam Hamza, Chief Executive Officer of Treatment. If qualified, the fund could help expedite several Treatment initiatives, such as the Global Library of Medicine (GLM), created to provide the highest level of qualified clinical support to healthcare professionals, ensuring enhanced diagnostic accuracy and transparency. The Library was developed with input from hundreds of healthcare professionals from around the world and utilizes proprietary algorithms. Though still growing, it currently comprises 1,000 of the most common clinically seen illnesses and over 10,000 symptoms. To underscore the accuracy of its platform, a non-medical student using Treatment’s medical diagnostic software for the Objective Structured Clinical Examination (OSCE), taken at medical, nursing and other professional healthcare schools, achieved a remarkable 92-per-cent success rate. Passing the OSCE – a mandatory annual exam that tests a student’s diagnostic aptitude – is a national requirement for graduation in 57 countries worldwide, including the U.S., Canada and U.K. The diagnostic software has operated with such accuracy, that the company has partnered with both the Mayo Clinic and the University of Minnesota, and is being used both to train medical students, and to help make quick, accurate diagnoses in hospitals. Treatment provides solutions for medical education and clinical information support. Its’ Medical Education Suite (MES) provides case-based clinical decision-making testing, grading and remedial action support for the next generation of healthcare professionals. That includes: Streamlining administrative duties such as automated history taking and chart note creation — helping eliminate 15-30% of healthcare spending that goes towards administrative waste.¹ Offering recommendations and double-checking work and treatment, by providing an explanation of every step and likelihood associated with various symptoms. Recommending appropriate tests and physical exams to support the accuracy of a diagnosis. “We are extremely excited with the power and accuracy of our AI medical diagnostic engine and the faith medical schools have in utilizing it, for testing and training the medical professionals of tomorrow,” says Dr. Hamza. “This underlying software is also the foundation of new products we are planning to launch in the healthcare marketplace later this year, in our mission to dramatically disrupt how healthcare is delivered worldwide.” With the challenges facing healthcare systems and professionals today, including burnout and staff shortages, the GLM aims to help mitigate many menial tasks such as history taking, chart notes and billing to allow for professionals to spend more quality time with patients. Separately, the National Institute of Health (NIH) in the U.S., is funding Treatment to help develop an artificial intelligence approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families. Current methods used by clinicians to collect family medical histories often do not satisfactorily capture important information from blended families or non-traditional relationships commonly found in racial or ethnic minority communities. In collaboration with Minneapolis-based Rush River Research, Treatment is using its proprietary AI capabilities to change how family health is collected and recorded to address existing disparities. The company held multiple focus groups with African-American doctors and community members to help develop and prototype culturally sensitive approaches to collecting information about family health. Treatment and Rush River Research have recently submitted an expanded Phase 2 grant proposal to the NIH to extend the work. The goal of the proposal is to move the prototype into a commercial solution which will promote adoption and integration into electronic health records and apps. “Old data approaches inevitably reflect old biases,” says Dr. Kevin Peterson, MD, MPH and Chief Medical Officer. “Treatment confronts issues of historical bias by reinventing how data about families is collected and stored to reflect the realities of modern life.” Meanwhile, Treatment has also partnered with aiXplain, the industry’s first no-code/low-code integrated AI development platform.to enable greater access to GLM by contributing to aiXplain’s ever-growing dynamic AI marketplace. Treatment and aiXplain also intend to explore mutually beneficial international opportunities through the partnership. Both parties have a shared interest in the future to provide the GLM in multiple languages. The collaboration also allows aiXplain and Treatment to work closely on testing and development of further new mutual joint commercial applications and/or solutions. The intent of this collaboration is to promote the development, installation, testing, validation and commercialization of one or more novel solutions that further the goals of both companies and proactively impact the health care market globally. For more information about Treatment.com AI’s products and services, please visit info@treatment.com Smith, J. (2024, April 18). The Future of Healthcare and AI. The Globe and Mail. Retrieved April 19, 2024, from theglobeandmail.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should
Treatment.com AI announces new additions to its Medical Education Suite (MES)
VANCOUVER, British Columbia, April 17, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is excited to announce two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite (“MES”) designed to educate the next generation of healthcare providers. Treatment’s MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking. It is designed to reduce faculty administration costs and time, provide a comprehensive range of clinical experiences, and offer students a digital self-test companion to enhance their understanding of diagnostic clinical approaches. The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical Examination). This established clinical exam is used in 57 countries to test the practical reasoning of healthcare professional students and measure their progress in clinical diagnosis and treatment. The market in the US alone comprises 300 medical schools; 900 nursing schools; 227,000 students and 145,000 residents/medical students. Treatment is also in discussions with schools in the UK and Canada. Treatment is excited to be announcing two new monthly subscription-based SaaS solutions for students, residents and all healthcare professionals expected to launch in the second half of 2024: AI Patient – utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics or on a ward. Both solutions are underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “I am delighted to announce this extension to our portfolio of solutions, especially given its focus on the next generation of clinicians. Our goal is for students to be supported and excel during their medical education, but can then utilize the same trusted platform as they move into practice.” Additionally, the Company has granted 800,000 Restricted Share Units (the “RSUs”), valid for a three year term, to consultants and an officer of the Company. The RSUs are issued pursuant to the Company’s share compensation plan and a portion are subject to vesting conditions. The RSUs are subject to a statutory hold period of four months and one day from issuance. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI partners with aiXplain Inc. to extend access to its Global Library of Medicine (GLM)
VANCOUVER, British Columbia, April 10, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with aiXplain, Inc. (“aiXplain”) to enable greater access to Treatment’s proprietary Global Library of Medicine (“GLM”) by contributing to aiXplain’s ever-growing dynamic Artificial Intelligence (AI) marketplace. Treatment has partnered with aiXplain, the industry’s first no-code/low-code integrated AI development platform. Over the past 7 years and in collaboration with hundreds of healthcare professionals globally, utilizing proprietary algorithms, Treatment has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). aiXplain’s marketplace makes it possible for healthcare organizations to access Treatment’s AI engine through its development framework and enhance the quality of clinical diagnosis within their organizations across multiple platforms. Treatment and aiXplain also intend to explore mutually beneficial international opportunities through the partnership. Both parties have a shared interest in the future to provide the GLM in multiple languages. The collaboration also allows aiXplain and Treatment to work closely on testing and development of further new mutual joint commercial applications and/or solutions. The intent of this collaboration is to promote the development, installation, testing, validation, and commercialization of one or more novel solutions that further the goals of both companies and proactively impact the healthcare market globally. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “The opportunity to partner with aiXplain, an organization at the heart of the AI evolution, and to be part of their evolving marketplace is fantastic. It helps fulfill our shared philosophies in the democratization of AI. Our goal is to have Treatment’s Global Library of Medicine (GLM) AI accessible to healthcare organizations and healthcare professionals alike, and aiXplain’s marketplace creates new opportunities for all parties.” “Our partnership with Treatment represents another quality addition to our world-leading marketplace of AI models and assets,” said Hassan Sawaf, CEO & Founder of aiXplain. “The news also marks a milestone for aiXplain. This is the first specialized AI model for the healthcare industry to join our marketplace, expanding the versatility of our AI platform across sectors.” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. About aiXplain Inc. Founded in 2020, aiXplain has established itself as a pioneering force with the industry’s premier no-code/low-code platform for AI development. Designed to democratize the creation and deployment of AI solutions, our platform empowers users to effortlessly develop, manage, benchmark, and deploy AI solutions. With access to an expansive marketplace featuring over 40,000 leading AI models and assets, our customers are equipped to tailor advanced solutions to their specific needs, streamlining the path from concept to deployment. To learn more, visit aixplain.com. Media Contact LaunchSquad for aiXplain aixplain@launchsquad.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email at info@treatment.com For media inquiries, contact: media@treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI welcomes the Federal Government’s announcement of a plan to fund $2.4 billion in its upcoming budget towards Artificial Intelligence (AI) Adoption
VANCOUVER, British Columbia, April 08, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) welcomes Prime Minister Justin Trudeau’s announcement on 7th April, 2024, that the federal government plans to fund $2.4 billion in its upcoming budget towards build capacity in Artificial Intelligence (AI) adoption. The federal government’s announcement indicates an imminent consultation with industry on a new AI Compute Access Fund and an accompanying strategy to expand the sector in Canada. Prime Minister Trudeau said “We want to help companies adopt AI in a way that will have positive impacts for everyone,” and indicated that $200 million of the proposed funding will specifically go toward boosting the adoption of AI in sectors like agriculture, clean technology, and health care. As a Canadian company utilizing AI to positively disrupt the healthcare sector, Treatment welcomes this announcement. The AI healthcare market, valued at $11 billion in 2021, is projected to be worth $187 billion in 2030. With the input of hundreds of healthcare professionals globally and utilizing proprietary algorithms, Treatment has created the most comprehensive and integrated online medical library powered by AI – Global Library of Medicine (GLM). The GLM provides the highest level of qualified clinical and support to all healthcare professionals, ensuring enhanced diagnostic accuracy and transparency in every step of support provided. To underscore the accuracy of our platform, we recently announced that our AI software passed a medical clinical exam, exceeding 92% success rate Treatment AI Passes Medical School Clinical Exam with 92% Success Rate – Treatment.com AI) Further, with the challenges facing our healthcare systems today (such as burnout and staff shortages) and for healthcare professionals especially, the GLM can help mitigate many of today’s menial tasks such as history taking, chart notes, billing and ensure they are spending quality time with patients who need to be seen. In turn, this will have a positive impact on costs and cost allocation for our Healthcare organizations and governing bodies. Dr, Essam Hamza, CEO Treatment.com AI comments: “Globally and here in Canada, our healthcare systems are crying out for evolution and AI has a significant opportunity to positively disrupt healthcare vs most other industries.Therefore, this announcement by the federal government comes at an opportune time. The future of healthcare delivery is going to look completely different than what it looks like today, through increased utilization of credible and pertinent AI solutions like what we’ve created at Treatment.com AI. We look forward to participating in imminent discussions with the federal government.” About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email: info@treatment.com For media enquiries contact: media@treatment.com Call: +1 (612) 788-8900 / Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity
VANCOUVER, British Columbia, March 27, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that the Company has received funding from The National Institute of Health (“NIH”) to develop a culturally sensitive AI approach for collecting family medical history. Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families. Current methods used by clinicians to collect family medical histories often do not satisfactorily capture important information from blended families or non-traditional relationships commonly found in racial or ethnic minority communities. The historical trauma and systemic bias common in African American communities can limit the amount of information known about the health of relatives. Without better methods for capturing information, existing health disparities addressing prevention and risk can persist. In collaboration with Rush River Research, Treatment is using its proprietary artificial intelligence capabilities to change how family health is collected and recorded to address existing disparities. The Company held multiple focus groups with African American doctors and community members to help develop and prototype culturally sensitive approaches to collecting information about family health. As part of their work building the world’s most comprehensive and integrated online medical library powered by AI (the Global Library of Medicine), Treatment is aggressively acting to ensure that diagnostic and treatment information in the future will be provided by platforms that are free of the inequity commonly reflected in medical AI programs today. By convening focus groups of African Americans to evaluate Treatment’s platform and provide insights and suggestions, the company ensures a rich and diverse perspective will inform the platform’s continuous improvement. The family history solution has been initially developed through a prototype that integrates into the Treatment AI platform. As continued improvements in the solution are made, they will be provided to Treatment for testing and implementation into future generations of the Global Library of Medicine platform. Treatment and Rush River Research have recently submitted an expanded Phase 2 grant proposal to the NIH to extend the work. The goal of the proposal is to move the prototype into a commercial solution which will promote adoption and integration into electronic health records and online apps. Kevin Peterson MD, MPH, FRCS(Ed), FAAFP, Chief Medical Officer, stated: “Old data approaches inevitably reflect old biases. Treatment confronts issues of historical bias by reinventing how data about families is collected and stored to reflect the realities of modern life.” FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about Treatment’s products and services, please email: info@treatment.com For media enquiries contact: media@treatment.com Call: +1 (612) 788-8900 / Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI inc. Announces Debt Settlement Transactions
Vancouver, British Columbia, March 21, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) announces that it proposes to enter into debt settlement agreements with certain arms’ length creditors (the “Creditors”) to settle an aggregate of CAD$461,307.40 in debt (the “Debt”). The Debt relates to outstanding principal and accrued interest on the Company’s 8% unsecured convertible debentures issued on May 17, 2022. In settlement of the Debt, the Company will issue an aggregate of 1,153,266 units of the Company (the “Units”) at a deemed price of $0.40 per Unit (the “Debt Settlement”), with each Unit to be comprised of one common share in the capital of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant a “Warrant”). Each whole Warrant will entitle the holder thereof to purchase one additional Share (a “Warrant Share”) at a price of $0.60 per Warrant Share for a period of 24 months from the date of issuance. All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The securities issued pursuant to the Debt Settlement have will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com 1 (612) 788-8900 Toll Free: 1 (888) 788-8955 Cautionary Statement The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy of accuracy of this news release. This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Debt Settlement, the entering into and consummation of the debt settlement agreements with the Creditors, and the Closing of the Debt Settlement are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Treatment AI Passes Medical School Clinical Exam with 92% Success Rate
VANCOUVER, British Columbia, March 20, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate. Treatment gave a third-year non-medical college student the Treatment mobile app and had them join a class of third-year medical school students taking their annual clinical exam. The OSCE exam is a standard exam given at medical, nursing and other professional healthcare schools. They are integral in medical education, as they allow a student to practice and demonstrate clinical diagnostic skills in an artificial medical scenario. During the exam, students enter an exam room to assess an actor who has been instructed on imitating a patient with a specific disease. Passing the OSCE is a national requirement for graduation in 57 countries worldwide (including US, Canada and United Kingdom) for medical and nursing students. In this case, Treatment gave the student its Treatment AI mobile app and sent them in to examine 12 ‘simulated’ patients. The student used the app to ask the patient questions, then left the room and wrote a clinical note summarizing the findings and suggesting the most likely possible diagnoses. The college student, with no previous medical training, entered the simulated patient’s age, sex, and initial symptom, and followed the prompts to complete an individualized assessment.The student then used the information summarized by the application to write a medical note describing the history, exam, recommended labs, and diagnoses. The student passed the exam, getting 11 of 12 “1st most likely” diagnoses correct. This included the student successfully making a variety of complex diagnoses including colon cancer, appendicitis, acute myocardial infarction, diabetes, and patellar tendonitis. Dr. Kevin Peterson, MD, MPH, Chief Medical Officer stated “The ability of the AI software to identify the pertinent positives and negatives, together with physical exam findings, and turn them into a precise description and reasoned differential diagnoses was remarkable. This is an AI tool that any medical professional can use in their pocket.” Dr. Essam Hamza, MD, CEO of Treatment.com AI added “We are extremely excited with the power and accuracy of our AI Medical diagnostic engine and the faith medical schools have in utilizing it, for testing and training the medical professionals of tomorrow. This underlying software is also the foundation of new products we are planning to launch in the healthcare marketplace later this year, in our mission to dramatically disrupt how healthcare is delivered worldwide” Treatment.com AI provides solutions for medical education and clinical information support. The Medical Education Suite (MES) provides case-based clinical decision making testing, grading and remedial action support for the next generation of healthcare professionals. The goals for MES are to enable better performance for Medical School students in their national exams (including OSCE) and for Schools, to reduce administration and exam creation costs, as well as minimizing valuable time for faculty in administering and grading exams. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about our products and services including our OSCE support, please email: info@treatment.com For media enquiries contact: media@treatment.com Call: +1 (612) 788-8900 / Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.